Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 6, 610 (2000)
doi:10.1038/76149
NIH researchers receive cut-price BRCA test
Tom Hollon1
- Bethesda
Myriad Genetic Laboratories, the Utah-based company that owns the patents on the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, has struck a deal with the US National Institutes of Health (NIH) for cut-rate prices on its gene tests in exchange for research data. Myriad might be hoping that its action goes some way toward defusing criticism of the company regarding its management of the BRCA-testing business.
To read this story in full you will need to login or make a payment (see right).
